COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact
Abstract Trial results for two COVID-19 vaccines suggest at least 90% efficacy against symptomatic disease (VEDIS). It remains unknown whether this efficacy is mediated by lowering SARS-CoV-2 infection susceptibility (VESUSC) or development of symptoms after infection (VESYMP). We aim to assess and...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Nature Portfolio
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/2eab7a70fea74c65a94d95d63fb05ed5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|